NRD
APLT

Nebula Research & Development’s Applied Therapeutics APLT Stock Holding History

Nebula Research & Development’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,531
Closed -$141K – 898
2024
Q3 		$141K Buy
+16,531
New +$97.4K 0.02% 859

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nebula Research & Development's APLT Position: Q4 2024 in Review

Nebula Research & Development sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 16,531 shares — an estimated $141K sold.

Nebula Research & Development first reported a position in APLT in Q3 2024 and held it in 1 quarter. The position peaked at $141K in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

  • Nebula Research & Development reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 16,531 Applied Therapeutics shares in Q4 2024, an estimated $141K.
  • Nebula Research & Development first reported a position in Applied Therapeutics in Q3 2024 and held it in 1 quarter.
  • Nebula Research & Development's Applied Therapeutics position peaked at $141K in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.